Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SORD | Q00796 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21713045 | 1.00 | KLKB1 (0.34) | KLKB1KDM4EALDH1A1GAASORD | |
| SCHEMBL21713046 | 1.00 | KLKB1 (0.34) | KLKB1KDM4EALDH1A1GAASORD | |
| SCHEMBL23768883 | 0.85 | ALDH1A1 (0.37) | KDM4EALDH1A1GAASORDPDE10A | |
| SCHEMBL21713019 | 0.84 | KLKB1 (0.38) | KLKB1PDE10AMAP4K4 | |
| SCHEMBL21713020 | 0.84 | KLKB1 (0.38) | KLKB1PDE10AMAP4K4 | |
| SCHEMBL21736665 | 0.84 | KLKB1 (0.38) | KLKB1PDE10AMAP4K4 | |
| SCHEMBL31033193 | 0.84 | KLKB1 (0.38) | KLKB1PDE10AMAP4K4 | |
| SCHEMBL21712992 | 0.83 | SMPD3 (0.39) | KLKB1PDE10A | |
| SCHEMBL21713091 | 0.79 | KLKB1 (0.36) | KLKB1KDM4EALDH1A1GAANPC1 | |
| SCHEMBL31033243 | 0.79 | KLKB1 (0.36) | KLKB1KDM4EALDH1A1GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3837252-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054617-A1 | Heteroaromatic Carboxamide Derivatives as Plasma Kallikrein Inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885KDM4E 337/4885ALDH1A1 1415/4885 |
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885KDM4E 337/4885ALDH1A1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.